Compare DexCom, Inc. (DXCM) vs Vanguard S&P 500 ETF (VOO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Vanguard S&P 500 ETF — how do they compare? DexCom, Inc. trades at $84.14 (market cap $31.86B), while Vanguard S&P 500 ETF trades at $716 (market cap $1.80T). The key difference: Vanguard S&P 500 ETF is far larger — about 56.5× DexCom, Inc.'s market cap, and Vanguard S&P 500 ETF is trading nearer its 52-week high, DexCom, Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and Vanguard S&P 500 ETF for 55 Days on average.
| DXCM | VOO | |
|---|---|---|
Market Cap | $31.86B | $1.80T |
Volume | 3,607,070 | 4,722,271 |
Sector | Health | Broad Market / Factor |
52-Week High | $92.34 | $716.17 |
52-Week Low | $54.84 | $580.93 |
Typical Hold Time | 62 Days | 55 Days |
Enterprise Value | $31.32B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $84.11, down 0.23% on the day, with a bearish technical signal but strong fundamental performance. The company reported Q2 2026 EPS of $0.70, beating expectations, and has shown consistent revenue growth, with 2025 revenue reaching $4.66 billion and net income of $836.3 million. Analyst consensus is strongly bullish with an 80.77% buy rating and a $95.07 price target. Recent news highlights growth opportunities in Type 2 diabetes care and key executive promotions.
The outlook for DXCM is positive due to robust earnings beats, expanding market opportunities, and strong institutional support. However, risks include competitive pressures, reimbursement challenges, and a high valuation with a P/E of 33.38. The stock presents a growth opportunity but requires monitoring of execution against these risks.
VOO trades at $715.68, up 0.18% with a bullish technical signal from moving averages. The ETF shows neutral momentum oscillators with RSI at 68.50 suggesting mild overbought conditions. Recent news highlights VOO's role in long-term wealth building despite short interest increasing 46.9% in September. Dividend yield remains modest with the next payment scheduled for September 30, 2026.
Outlook remains positive given S&P 500 exposure and historical resilience, though risks include potential profit growth slowdown from 35% to 15% in 2027 and elevated short interest. The ETF's low-cost structure and diversification provide stability amid market volatility, making it suitable for core portfolio holdings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Vanguard S&P 500 ETF
VOO is a foundational ETF that tracks the S&P 500 Index, providing exposure to 500 of the largest and most established companies in the United States. Renowned for its ultra-low expense ratio and tax efficiency, it serves as a core building block for long-term investors seeking to capture the total return of the U.S. large-cap market in a single, highly liquid vehicle.
Read more on VOO →
